愛爾眼科(300015.SZ)與眾生藥業簽署戰略合作框架協議
格隆匯10月22日丨愛爾眼科(300015.SZ)公佈，公司於2019年10月22日與廣東眾生藥業股份有限公司(“眾生藥業”)簽署了《戰略合作框架協議》。
眾生藥業為中國製藥工業百強企業，是一家集藥品研發、生產和市場營銷為一體的國家火炬計劃重點高新技術企業，目前的主營業務是中成藥、化學藥、中藥材和中藥飲片、化學原料藥的研發、生產和銷售，以及眼科的醫療服務和運營管理。
協議（甲方：廣東眾生藥業股份有限公司：乙方：愛爾眼科醫院集團股份有限公司）顯示：
雙方通過建立密切、可持續發展的合作關係，提升雙方在醫藥市場的競爭力和影響力，充分挖掘和發揮雙方各自核心資源優勢，實現優勢互補和業務聯動發展，共同促進技術、產品與服務的延伸和發展，在共同發展的基礎上實現雙贏的戰略合作關係。
雙方主要圍繞眼科醫療領域、眼科投資領域、眼科藥品研發領域、眼科藥品推廣領域等多方面開展深度合作，創造更大的合作商業價值，以期共同實現雙方在眼科領域的戰略願景。
此次合作內容：1、雙方同意在眼科醫療服務領域形成深度合作，具體合作形式可由甲乙雙方簽訂正式的合作協議進行約定。2、雙方將依託各自在技術、產品、產業資源上的優勢，藉助甲方的創新藥開發經驗，乙方的藥物藥效評價及臨牀開發經驗，並結合乙方的醫療資源，共同探求新藥開發機會，共同打造具有全球競爭力的眼科創新藥物。3、甲乙雙方可共同就甲方已開發的眼科藥物進行臨牀評價和臨牀開發方面的合作，並可按照雙方認可的估值對甲方在研眼科產品探討合作投資事項。4、乙方將甲方眼科產品列入乙方及乙方旗下醫院的基本用藥目錄。雙方同意就學術推廣、患者教育等市場支持方面開展相應的合作。5、雙方同意相互為彼此的合作事項創造最惠條件和待遇，共同形成戰略合作伙伴。具體的合作事項以雙方簽署的合作協議為準。
公司與眾生藥業簽署戰略合作框架協議，建立密切、可持續發展的合作關係，充分挖掘和發揮雙方各自核心資源優勢，實現優勢互補和業務聯動發展，共同促進技術、產品與服務的延伸和發展。通過此次合作，實現雙方未來在產品研發、產供合作方面創造更大的合作商業價值，符合公司和全體股東的利益，有利於公司持續健康穩健發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
